



Proteomics International

LABORATORIES LTD

ASX release

12 November 2025

ASX code: PIQ

Proteomics International receives \$2.2 million in R&D tax incentive

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to announce that its cash reserves have been further strengthened by the receipt of \$2.2 million in research and development tax incentive for the 2024-25 financial year.

Proteomics International's business model sees the Company pursue ground-breaking R&D with blue-sky potential in next generation diagnostic tests using its disruptive Promarker® technology platform. This R&D is also supported by revenue generated from providing sophisticated analytical services to the biopharmaceutical and life science industry.

The funding helps to underpin the continued development of the Company's suite of diagnostic tests as they enter their commercialisation phases, along with the advance of Proteomics International's rich pipeline of diagnostics tests in R&D:

- Promarker®D - a predictive test for Diabetic Kidney Disease
- Promarker®Endo - a diagnostic test for Endometriosis
- Promarker®Eso - a diagnostic test for Esophageal Cancer
- OxiDx - a test to measure oxidative stress and track athletic training-related muscle stress
- The Promarker® diagnostics pipeline including asthma, COPD and complications of diabetes

In 2024-25, Proteomics International Laboratories Ltd and its subsidiaries spent \$5.15 million on R&D, enabling the Company to receive an Australian Government rebate of \$2,241,476.

The Federal R&D tax incentive encourages companies engaging in beneficial research to Australia by providing a cash rebate of 43.5% for qualifying activities.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe

Managing Director

Proteomics International Laboratories Ltd

T: +61 8 9389 1992

E: enquiries@proteomicsinternational.com

Matthew Wright

Media and Public Relations

NWR Communications

T: +61 451 896 420

E: matt@nwrcommunications.com.au

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Dirk van Dissel
Investor Relations & Corporate Advisory
Candour Advisory
T: +61 408 326 367

Proteomics International (Europe)
Plesmanweg 9, 7602 PD Almelo
The Netherlands
T: +31 85 40 11 173

For personal use only

Proteomics International Laboratories Ltd
ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com